PAIN THERAPEUTICS WKN: A2PGL8 ISIN: US14817C1071 Kürzel: SAVA Forum: Aktien Thema: Hauptdiskussion
2,41 USD
+2,55 %+0,06
24. Dec, 02:00:00 Uhr,
Nasdaq
Kommentare 11.826
Summer.76,
28.02.2023 15:49 Uhr
1
Cassava Sciences GAAP EPS of -$0.47 beats by $0.11
https://seekingalpha.com/news/3941853-cassava-sciences-gaap-eps-of-0_47-beats-0_11
• Cassava Sciences press release (NASDAQ:SAVA): Q4 GAAP EPS of -$0.47 beats by $0.11.
• At December 31, 2022, cash and cash equivalents were $201 million, compared to $233.4 million at December 31, 2021, with no debt. Year-end cash balance included net proceeds of $47.3 million from the sale of 1.7 million shares of common stock completed in November 2022.
• Net cash use for operations for the first half of 2023 is expected to be approximately $45 to $50 million, driven primarily by expenses for our clinical program in Alzheimer’s disease.
Summer.76,
28.02.2023 15:48 Uhr
0
https://www.globenewswire.com/news-release/2023/02/28/2617230/8339/en/Cassava-Sciences-Reports-Full-year-2022-Financial-Results-and-Operating-Updates.html
Marco1976,
17.02.2023 23:36 Uhr
0
https://www.instagram.com/reel/CokiE0IIwDE/?igshid=YmMyMTA2M2Y=
G
GoldenNugget,
14.02.2023 20:03 Uhr
0
🤷♂️🤢🤬
P
PT80,
14.02.2023 19:04 Uhr
0
Warum heute der Absturz?
oxanabanana,
08.02.2023 15:29 Uhr
0
953 Alzheimer’s Patients Are Now Enrolled Across Phase 3 Studies
Both Phase 3 Studies Have Passed the Halfway Mark for Enrollment
Goal Is to Complete Enrollment for Both Phase 3 Studies by Year-End 2023
AUSTIN, Texas, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced an update on patient enrollment for its on-going Phase 3 clinical studies of simufilam for the treatment of Alzheimer’s disease dementia. Simufilam, an oral drug, is Cassava Sciences’ proprietary lead drug candidate.
James W. Kupiec, MD, Chief Medical Officer of Cassava Sciences, commented, “We are pleased with the recent pickup in the pace of patient enrollment with our Phase 3 studies, which are designed to evaluate the safety and efficacy of simufilam in patients with Alzheimer’s disease.”
A total of 953 Alzheimer’s patients are now enrolled across Cassava Sciences’ Phase 3 studies. For each Phase 3 study, patient enrollment has passed the halfway mark of the target patient enrollment. The enrollment target for both (not each) Phase 3 clinical studies is approximately 1,750 patients with mild-to-moderate Alzheimer’s disease who also meet other study eligibility criteria. There are no interim analyses in Cassava Sciences’ Phase 3 studies.
“We anticipate the completion of patient enrollment for both of our Phase 3 studies by year-end 2023,” said Remi Barbier, Present & CEO. “Based on recent enrollment trends, we think this is a realistic expectation for completing patient enrollment.”
Özgün,
02.02.2023 18:33 Uhr
0
Hoffen wir es Mal 🙏🏻
Özgün,
02.02.2023 18:06 Uhr
0
https://www.marketbeat.com/instant-alerts/nasdaq-sava-sec-filing-2023-02-02/
Trithon2022,
02.02.2023 17:09 Uhr
0
Was ist passiert? Mich hat was geweckt.
DerBaB,
01.02.2023 6:13 Uhr
0
Bleibt interessant hier,hätte damals nicht verkaufen sollen...
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | MUTARES Hauptdiskussion | -1,04 % | |
2 | XIAOMI CORP. CL.B Hauptdiskussion | +0,91 % | |
3 | DPCM Capital Hauptdiskussion | +22,85 % | |
4 | Microvast | +24,84 % | |
5 | Brainchip Klassengruppe | +24,59 % | |
6 | TeamViewer Hauptdiskussion | +2,81 % | |
7 | AMAZON Hauptdiskussion | +0,06 % | |
8 | Blackrock | +0,99 % | |
9 | ENI Hauptdiskussion | +0,17 % | |
10 | Canopy Hauptforum | +1,41 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | MUTARES Hauptdiskussion | -1,04 % | |
2 | XIAOMI CORP. CL.B Hauptdiskussion | +0,91 % | |
3 | DPCM Capital Hauptdiskussion | +22,85 % | |
4 | Microvast | +24,84 % | |
5 | Brainchip Klassengruppe | +24,59 % | |
6 | TeamViewer Hauptdiskussion | +2,81 % | |
7 | AMAZON Hauptdiskussion | +0,06 % | |
8 | Blackrock | +0,99 % | |
9 | ENI Hauptdiskussion | +0,17 % | |
10 | Canopy Hauptforum | +1,41 % | Alle Diskussionen |